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surveyed the laboratory analytical data of urine and non-urine cases collected through the
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Analytic Laboratory Drug Abuse Report System (ALDARS) and estimated the illicit drug use
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trends in Taiwan from 1999 to 2011. These samples were collected from suspects who were
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arrested for possessing and/or taking illicit drugs. Descriptive statistics were used to report
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the distribution rate and patterns of drug abuse. In addition, linear regression was applied
to determine the trends of drug abuse. The results showed that methamphetamine was the
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most widely used illicit drug. The heroin abuse situation might have been under control,

Designer drugs

but that of ketamine may have become worse. Furthermore, an increasing trend was

Drug abuse

observed for the abuse of “designer drugs” since 2004. Phenylalkylamines was the main

Trends

“designer drug”. Chloroamphetamine (CA) was first notified in 2009. Subsequently, the drug
has been experiencing an abuse situation, although it was considered to show no abuse
potential. In summary, this study could further predict that ketamine and “designer drugs”,
such as phenylalkylamines and synthetic cannabinoids, might remain popular among drug
users in Taiwan. The prevalent status of the emerging drugs in Taiwan and that in western
countries may be synchronized.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. All rights reserved.

1.

Introduction

Since the middle of the 20th century, drug abuse has become a
major public health problem, with a great deal of consequences throughout society. The problems derived from drug
abuse involve injuring one’s physical health, rising crime rates
and numbers of victims of domestic violence, increasing
prevalence of infectious illnesses (including HIV/AIDS, hepatitis B virus, and hepatitis C virus), joblessness, homelessness,

and failure in school. According to the World Drug Report 2012
of the United Nations Office on Drugs and Crime (UNODC), the
global drug abuse population accounts for 230 million in the
world [1]. In Taiwan, approximately 1.43% of persons aged
12e64 years (252,000 people) used drugs at least once in 2009
[2].
Between 1990 and 2002, studies were performed using drug
urine tests on arrested individuals in Taiwan. The results
showed that amphetamines and opiates were the major illicit
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Fig. 1 e The number of collected urine and non-urine cases, 1999e2011.

drugs. More amphetamine positives were found relative to
opiate ones [3,4]. In 2002, the cases of 3,4-methylenedioxy-Nmethamphetamine (MDMA) and ketamine abuse were less
than those of amphetamines and opiates. MDMA and ketamine users were younger than amphetamine and opiate ones
[4].
The data gathered from laboratory analytical results can
provide opportune information on the current status of drug
abuse. It can support drug scheduling efforts [5] and can also
help in policy decisions on drug abuse prevention. In Taiwan,
the Analytic Laboratory Drug Abuse Report System (ALDARS)
can systematically and fully gather nationwide identification
of cases, including urine and non-urine samples, which were
collected from suspects arrested for possessing and/or taking
illicit drugs. The system can associate information from these
cases, which were analyzed by national forensic laboratories
including the Taiwan Food and Drug Administration (TFDA),
municipal governments, county and city health bureaus, the
Ministry of Justice Investigation Bureau, the National Police
Administration Criminal Investigation Bureau, the Armed
Forces Police Command, as well as certified urine drug testing
laboratories. The ALDARS was developed and previously
managed by the National Bureau of Controlled Drug (NBCD).
After 2010, the NBCD, the Bureau of Food Safety, the Bureau of
Pharmaceutical Affairs, and the Bureau of Food and Drug
Analysis were consolidated into TFDA. All missions of the
NBCD were transferred to the TFDA.
In Taiwan, the Statute for Narcotics Hazard Control is an
ordinance to regulate the manufacture, purchase, possession,
or distribution (sale, trade, or gift) of illicit drugs. Illicit drugs
are classified into four schedules according to their potential
for addiction, abuse, and harm to society. A person will be
arrested and punished if he/she takes illicit drugs that are
listed in Schedules 1 or 2 of the Statute. There was no punishment for a person who takes Schedules 3 or 4 illicit drugs
until May 2009.

On the basis of making an effective policy on drug
enforcement and drug abuse prevention, this study aimed to
estimate the situation of drug abuse using the data from the
ALDARS from 1999 to 2011. It not only provides detailed information on the prevalence and types of controlled drugs and
emerging drugs, but also can be used to support drug scheduling decisions.

2.

Methods

2.1.

Data sources

This study estimated the illicit drug use trends from 1999 to
2011, using analytical data from the ALDARS. The data from
ALDARS consisted of information on the urine tests of drug
abusers and drug seizures. These samples were collected from
suspects who were arrested for possessing and/or taking illicit
drugs. In total, 738,540 urine samples and 370,106 non-urine
cases were surveyed. Fig. 1 presents the total cases of urine
and non-urine samples annually from 1999 to 2011.

2.2.

Statistical analysis

Data analysis was performed with the Statistical Package for
the Social Sciences (SPSS) Statistics 17.0 for Windows (SPSS
Inc., Chicago, IL, USA). Descriptive statistics were used to
report the distribution rate and patterns of drug abuse. In
addition, linear regression was applied to determine the
trends of drug abuse. The beta coefficient was only reported as
significant if the p value was less than 0.05.

2.3.

Restrictions of study

The laboratories would submit the results of the seizures that
contained drugs and substances to ALDARS. Because the
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Fig. 2 e The distribution rates of urine and non-urine cases that were identified with morphine or codeine from 1999 to
2011. COD [ codeine; MOR [ morphine.

positive rate of seizures cases could not be showed, this study
presents the distribution rate of special drugs in the total
specimen instead of its positive rate.
Urine samples are considered biological specimens. After
drug consumption, the parent drugs or their metabolites can
be detected in urine samples. However, the concentrations of
drugs and their metabolites in urine are affected by several
factors, including the time of collection of urine, the amount
of drug, the frequency of abuse, fluid intake, body shape,
metabolic factors [6], and the analytical methods used. In
Taiwan, the regulations governing urine testing operations for
drug abuse are applicable to test and judge illicit drugs in urine
samples, which need to be analyzed with an initial test and/or
a confirmatory test. However, the initial and confirmatory
tests for emerging drugs have not been developed. Therefore,
the status of abuse of emerging drugs in urine samples was
not be surveyed in this study.

3.

Results and discussion

3.1.

Multiple drug abuse

The objective of this study was first to survey the situation of
multiple drug abuse. Fig. 2 shows the estimated distribution
percentage of a single drug that was identified in a urine or
non-urine sample. From 1999 to 2011, the distribution percentage of a single drug identified in non-urine samples was
considerably varied, while that identified in urine samples
decreased during the period of 1999 to 2006, but increased
from 2007.
From 2003 to 2011, there is a big difference in the trends of
multiple drugs between urine and non-urine samples. Codeine can be detected in the urine samples of heroin users

because street heroin contains codeine [7]. As shown from
the distribution percentage of urine samples containing
morphine (a metabolite of heroin) versus codeine (Fig. 2), it
could be inferred that heroin seizures might always involve
codeine and heroin abusers who use heroin with other drugs,
such as codeine [6].

3.2.

The most common drugs of abuse

Fig. 3 shows the distribution rate of the top four most
commonly identified drugs including methamphetamine,
heroin, ketamine, and MDMA in urine and non-urine samples
from 1999 to 2011.

3.2.1.

Methamphetamine

As shown in Fig. 3, from 1999 to 2011, the distribution percentages of methamphetamine identified in urine and non-urine
samples were over 47% and 25%, respectively. From 1999 to
2001, these distribution rates were higher than those of heroin,
but lower from 2002 to 2008. However, an increasing trend was
observed since 2009. In addition, decreasing trends were
observed from 1999 to 2001, but trends fluctuated considerably
in the period from 2002 to 2011. Linear regression was applied,
and the estimated beta coefficient of the trend of urine samples
was 0.018 with a p value less than 0.05 (data not shown).
In the early 1990s, methamphetamine was the predominant drug of abuse, and it remained steady into the late 1990s
[8]. Moreover, from the data collected by the law enforcement
agency, the seized quantities of methamphetamine and its
precursors have remained in first or second place since 1999.
In short, it could indicate that the population who used
methamphetamine has diminished and maintained a stable
status. However, methamphetamine remained the primary
illicit drug of concern.
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Fig. 3 e The distribution rates of urine and non-urine cases containing the four most frequently identified drugs in Taiwan
from 1999 through to 2011. Morphine is a metabolite of heroin. K [ ketamine; MA [ Methamphetamine; MDMA [ 3,4methylenedioxy-N-methamphetamine; MOR [ morphine.

3.2.2.

Heroin

The percentage of heroin identified in urine samples was over
50% from 2002 to 2008 (Fig. 3). It showed a fluctuating trend,
which has decreased since 2009. In the period from 2003 to
2008, the distribution rate of heroin seizures remained a
considerably fluctuating trend, but it decreased since 2009.
The abuse of heroin, the most problematic drug type, has
been under control recently. Regarding the statistics from the
Taiwan Centers for Disease Control, the injection of illicit
drugs has been the primary risk factor for HIV infection since
2004. To reduce the prevalence of HIV infection among injection drug users, the drug abuse prevention strategies on harm
reduction were implemented and the drug reuse prevention
centers were established under the county or city government
in 2006. Linear regression was applied to determine the trends
of drug abuse from 2006 to 2011. The estimated beta coefficients of urine and non-urine samples were 7.91 and
8.55, respectively, and their p values were less than 0.05 (data
not shown). These results indicated a significantly descending
trend of heroin abuse.

3.2.3.

Ketamine

The study found that the distribution rates of ketamine in
urine and non-urine samples have been increasing since 2000
(Fig. 3). Linear regression was applied to assess the status of
drug abuse from 1999 to 2011. The estimated beta coefficients
of urine and non-urine samples were 0.17 and 0.023, respectively, and both p values were less than 0.01 (data not shown),
indicating a worsening situation of ketamine abuse over years.
In Taiwan, the number of ketamine seizures has been rising at an alarming pace. The abuse of ketamine has risen since
the early 2000s [8]. Club drugs, such as MDMA and ketamine,
are the most widely used at night clubs, Karaoke Television
(KTVs), and dance parties to enhance social intimacy and
sensory stimulation. Ketamine, a structural analog of phencyclidine, is always taken with MDMA. It can produce hallucinations and out-of- body subjective experiences similar to
near-death experiences. Due to its anesthetic effect,

ketamine has abuse potential [9]. One illicit drug peddler
alleged that the use of ketamine is not a crime because it has
no addiction potential and it does not display the hazards of
heroin. Moreover, owing to its low cost, the main age group of
ketamine users consists of persons aged below 29 years [10].
Due to curiosity, young people usually use it for amusement
and share it with friends. Consequently, ketamine abuse has
become a serious problem among young people in Taiwan.

3.2.4.

MDMA

The study found that MDMA experienced an epidemic in 2002,
but the level of abuse decreased and remained stable from
2005 to 2010. However, it increased slightly in 2011 (Fig. 3).
MDMA was used as the most popular club drug. The World
Drug Report noted that MDMA has sprung up again in some
countries since 2011 [1], implying that MDMA might regain its
popularity after 2011.

3.3.

Abuse of emerging drugs

“Designer drugs” can be defined as unregulated new psychoactive substances whose chemical structures have been
slightly altered from that of a controlled drug. The effects of
these substances were shown to be similar to their parent
compounds [11]. These drugs are evolving rapidly and characterized by a large variety. As shown in Fig. 4, an estimated 32
types of “designer drugs” were discovered in Taiwan from
2004 to 2011. About two-thirds of these drugs were notified
after 2009. It showed that the types of “designer drugs” abused
might have become varied since 2009, with a trend similar to
that of other countries [11].
“Designer drugs” have been an ongoing challenge to law
enforcers and public health. This study showed that the
estimated number of seizure cases involving emerging drugs
increased from two in 2004 to 977 in 2011. According to the
linear regression result, the estimated beta coefficient was 129
and its p value was less than 0.001 (data not shown). This
indicated that the use of emerging drugs has been increasing
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Emerging Drugs

Pyrrolidinophenones

Piperazines

mPPP
(July 2011)
Benzyl-Piperazines
BZP (Apr. 2009)

Monomethoxy derivatives
PMA (Nov. 2004)
PMEA (May 2008)
PMMA (Jan. 2006)

Tryptamines

Synthetic Cannabinoids

Phenyl-Piperazines
mCPP (Feb. 2010)
pFPP (July 2010)
TFMPP (June 2009)

Dimethoxy derivatives
2C-B (Dec. 2004)
2C-C (June 2005)
2C-I (June 2005)
DMA (Feb. 2006)
DOB (Mar. 2008)

CP 47497 (Nov. 2010)
JWH-018 (Oct. 2010)
JWH-073 (Nov. 2010)
JWH-250 (Nov. 2010)

Halogen-containing compounds
CA (Apr. 2009)
FA (Aug. 2010)
FMA (Aug. 2011)

Phenylalkylamines

AMT (Oct. 2005)
5-MeO-AMT (Nov. 2007)
5-MeO-DIPT (Sep. 2005)
5-MeO-DMT (Oct. 2010)

-keto compounds
Butylone (May 2009)
MDPV (Aug. 2011)
Mephedrone (Jan. 2010)
Methcathinone (Feb 2010)
4-Methylethcathinone (June 2011)
Methylone (Sep. 2009)
Pentylone (Nov. 2011)

Others
N-Hydroxy-MDA
(July 2010)

Fig. 4 e The identified situation and the first notified time of emerging drug categories reporting to ALDARS, 2004e2011.
AMT [ alpha-methyltryptamine; ALDARS [ Analytic Laboratory Drug Abuse Report System; BZP [ N-benzylpiperazine;
CA [ chloroamphetamine; 2CeB [ 4-bromo-2,5-dimethoxyphenethylamine; 2CeC [ 4-chloro-2,5-dimethoxyphenethylamine; 2CeI [ 2,5-dimethoxy-4-iodophene-thylamine; DMA [ dimethoxyamphetamines; DOB [ 4-bromo-2,5dimethoxy-amphetamine; FA [ fluoroamphetamine; FMA [ fluoromethamphetamine; pFPP [ 1-(4-fluorophenyl)piperazine;
N-hydroxy-MDA [ N-hydroxy-3,4-methylene-dioxymethamphetamine; mCPP [ metachlorophenylpiperazine;
MDPV [ methylenedioxypyrovalerone; mPPP [ 4-methyl-pyrrolidinopropiophenone; 5-MeO-AMT [ 5-methoxy-amethyltryptamine; 5-MeO-DIPT [ 5-methoxy-N,N-diisopropyltryptamine; 5-MeO-DMT [ 5-methoxy- N,N-dimethyltryptamine; PMA [ para-methoxyamphetamine; PMEA [ para-methoxyethylamphetamine; PMMA [
paramethoxymethamphetamine; TFMPP [ 1-(3-trifluoromethylphenyl) piperazine.

sharply since 2004. Because these drugs are usually marketed
as “bath salts” or “plant food” [12] and labeled as “research
chemicals”, “party pills”, and “herbal highs”[13], it is difficult
for the law enforcement agency to detect and seize them.
Moreover, these drugs are always sold via the internet [13],
which accelerates their spread.

3.3.1.

Phenylalkylamines

According to the categorization by Wohlfarth and Weinmann
[14], most notable “designer drugs” are categorized as phenylalkylamines in Taiwan. As shown in Fig. 5, phenylalkylamines
were the primary emerging drugs of abuse. The estimated
number of cases involving phenylalkylamines increased from
two in 2004 to 872 in 2011. The estimated beta coefficient was
74 and its p value was 0.01 (data not shown). As shown in Fig. 6,
the four classes of phenylalkylamines found mainly included
monomethoxy derivatives, dimethoxy derivatives, beta-keto
compounds, and halogen-containing compounds.
From 2004 to 2007, monomethoxy derivatives such as
paramethoxyamphetamine (PMA), paramethoxymethamphetamine (PMMA), and para-methoxyethylamphetamine (PMEA)
were distributed among drug users in Taiwan. These drugs
appeared on the designer market since 1973 in foreign countries [15e17] and have been slowly notified since 2004 (Fig. 4).
They exhibit hallucinogenic and stimulant properties [14] and
are sold in tablet form labeled as “ecstasy” [18]. Their usage
peaked in 2007 but experienced a decline from 2008 to 2011
(Fig. 6). PMMA was the main designer drug (Fig. 7). From April to
July 2006, eight fatal intoxications involving PMMA ingestion
were reported [18]. PMMA was not added to the list of illicit
drugs under Schedule 3 of the Statute for Narcotics Hazard

Control until August 2006. Its usage began to decrease after
2007.
From 2008 to 2010, dimethoxy derivatives were used
among drug users in Taiwan. Subsequently, the use of dimethoxyamphetamines (DMA) became widespread. As shown in
Fig. 4, dimethoxy derivatives such as 2C series, which were
first notified in 1980 in other countries [19], were first reported
in Taiwan in 2004. Their usage peaked in 2008 and declined
from 2009 to 2010. Subsequently, the use of DMA has
increased since 2009 (Fig. 7). In Taiwan, 2CeB was first noted
in 2004 as a main designer drug (data not shown). It was
classified under Schedule 3 of the Statute for Narcotics Hazard

Fig. 5 e The cases of designer drugs reporting to ALDARS,
2004e2011. ALDARS [ Analytic Laboratory Drug Abuse
Report System.
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Fig. 6 e The cases that were identified as
phenylalkylamines, 2004e2011.

Control list in December 2005. An epidemic trend was
observed from 2006 to 2009, which may be attributed to the
fact that a person who took Schedule 3 or 4 illicit drugs was
not punished before 2009. On the other hand, DMA is regulated in Schedule 2 of the Statute for Narcotics Hazard Control
list. However, due to its amphetamine-like stimulating effect
[14], the use of DMA has begun to rise sharply since 2009.
Beta-keto compounds, which are analogs of MDMA, MDEA,
and MBDB, exhibit amphetamine- and MDMA-like effects.
Recently, these compounds have become a global phenomenon [14]. As shown in Figs. 4 and 6, seven new beta-keto
compounds have been notified and displayed a sharply
increasing trend since 2009. Both methylone and mephedrone
experienced a significant increase from 2010 to 2011 (data not
shown). Mephedrone was added as a controlled drug in July
2010. The status of mephedrone abuse decreased sharply in
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2011. By contrast, methylone was not scheduled in the Statute
for Narcotics Hazard Control list until September 2011. It is
predicted that the usage of methylone might decrease in the
future.
Halogen-containing compounds might be the next popular
“designer drugs”. Drugs like chloroamphetamine (CA), fluoroamphetamine (FA), and fluoromethamphetamine (FMA) can
produce central nervous system-stimulating effects like amphetamines [20,21]. CA was recognized to have no abuse potential [22]. The study showed that CA was first reported in
April 2009 (Fig. 4) with a total of 775 cases identified from 2009
to 2011 (Fig. 6). It was illegally manufactured or synthesized in
some clandestine laboratories. The detection and identification of CA in urine samples was also reported [23]. CA has been
regulated in Taiwan since June 2011. As far back as 2005, FA
abuse was first reported [21]. Subsequently, a large number of
drug preparations containing FA were seized [24,25]. The
study showed that FA abuse in Taiwan was first reported in
August 2010, after which the number of cases increased to 11
in 2011 (data not shown). FMA abuse was first reported in
Austria [26] in August 2011 (Fig. 4) and eight cases were reported (data not shown). According to a prior study, FA and
FMA had been analyzed in human biological samples [27] and
seizures [26], which indicated that these drugs might have
abuse potential.

3.3.2.

Synthetic cannabinoids

At present, synthetic cannabinoids have become more popular among drug users since their detection in legal herbal
blends that were substituted for cannabis [14]. As shown in
Fig. 4, there were six types of synthetic cannabinoids,
including CP47,497, JWH-018, JWH-073, JWH-250, JWH-081,
and JWH-203, found between 2010 and 2011. The estimated
number of cases increased from 25 in 2010 to 95 in 2011 (Fig. 5).
The effects of these drugs are similar to that of cannabis. In
Taiwan, marijuana is never the main drug of abuse. In fact,
with the increasing number of tourists, foreign laborers, and
foreign spouses in Taiwan, the behavior of drug abuse might
gradually be assimilated abroad.

3.3.3.

Piperazines

Piperazines act as stimulants and/or hallucinogens [11].
As shown in Fig. 4, both benzyl-piperazine and 3trifluoromethylphenylpiperazine were circulated among
drug users from the beginning of the 21st century [28] and
were first found in 2009. Subsequently, 1-(3-chlorophenyl)
piperazine appeared in 2010. The estimated number of cases
involving piperazines increased from three in 2009 to 25
(Fig. 5). This indicated that these drugs could become one of
the popular “designer drugs” in the future.
Fig. 7 e The non-urine cases that contained monomethoxy
and dimethoxy derivatives. 2C series [ 4-bromo-2,5dimethoxyphenethylamine (2CeB), 4-chloro-2,5-dimethoxyphenethylamine (2CeC), 2,5-dimethoxy-4-iodophenethylamine (2CeI); DMA [ dimethoxyamphetamines;
DOB [ 4-bromo-2,5-dimethoxyamphetamine;
PMA [ paramethoxyamphetamine;
PMMA [ paramethoxymethamphetamine; PMEA [
para-methoxyethylamphetamine.

3.3.4.

Tryptamines

The abuse of tryptamines, which have hallucinogenic effects
[14], was also found in Taiwan. 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT), also known as “Foxy” or “FoxyMethoxy”, is the most commonly used “designer drug”
among homosexual drug users in Taiwan. The abuse of this
drug exhibited a fluctuating trend (data not shown). The drug
was added to the list of illicit drugs in Schedule 3 of the Statute
for Narcotics Hazard Control in 2011.
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Conclusion

This study first reviewed the situation of drug abuse according
to the data collected through ALDARS from analytical laboratories in Taiwan. ALDARS can systematically and fully gather
nationwide identification results of cases including urine and
non-urine samples. These samples were collected from suspects arrested for possessing and/or taking illicit drugs.
The study showed that methamphetamine remains the
primary drug of abuse. The status of heroin abuse is recently
under control, while that of ketamine has worsened. In
addition, the abuse of CA is experiencing an epidemic in
Taiwan. Phenylalkylamines are the main emerging drugs of
concern and their abuse is increasing sharply. Synthetic
cannabinoids might be one of the ongoing popular “designer
drugs”. Above all, it is predicted that ketamine might remain
popular, and the trend of abuse of emerging drugs in Taiwan
has been synchronized with those of western countries. In
addition, “designer drugs” with stimulant and hallucinogenic
effects would experience an epidemic in the future if the authority is short of policy to regulate them.
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